A Bayesian network meta-analysis of randomized controlled trials comparing the efficacy and safety of cholinergic modulators in schizophrenia
Published online on December 01, 2025
Abstract
Journal of Psychopharmacology, Ahead of Print.
Background:Emerging evidence suggests that the cholinergic system, through its modulation of dopamine via muscarinic and nicotinic receptors, holds therapeutic promise in schizophrenia. Xanomeline (M1/M4 muscarinic agonist) with trospium (muscarinic ...
Background:Emerging evidence suggests that the cholinergic system, through its modulation of dopamine via muscarinic and nicotinic receptors, holds therapeutic promise in schizophrenia. Xanomeline (M1/M4 muscarinic agonist) with trospium (muscarinic ...